Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: metastatic hormone-sensitive prostate cancer (mHSPC) using a matching-adjusted indirect comparison (MAIC)
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Enzalutamide + ADT showed better efficacy than darolutamide + ADT for treatment of patients with mHSPC. These findings can help inform treatment decisions in clinical practice.
[AIMS] To compare the efficacy of enzalutamide + androgen-deprivation therapy (ADT) versus darolutamide + ADT for treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) using
APA
Armstrong AJ, Pandya BJ, et al. (2025). Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.. Future oncology (London, England), 21(19), 2459-2469. https://doi.org/10.1080/14796694.2025.2526324
MLA
Armstrong AJ, et al.. "Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.." Future oncology (London, England), vol. 21, no. 19, 2025, pp. 2459-2469.
PMID
40654300 ↗
Abstract 한글 요약
[AIMS] To compare the efficacy of enzalutamide + androgen-deprivation therapy (ADT) versus darolutamide + ADT for treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) using a matching-adjusted indirect comparison (MAIC).
[PATIENTS AND METHODS] Individual patient data from ARCHES (NCT02677896; enzalutamide + ADT, = 1150) were weighted and adjusted to match published aggregated data on baseline characteristics from ARANOTE (NCT04736199; darolutamide + ADT, = 669). The MAIC was anchored on the common comparator, placebo + ADT, and provided a (matching-adjusted) hazard ratio (HR) of enzalutamide versus darolutamide.
[RESULTS] Treatment with enzalutamide + ADT significantly prolonged the primary endpoint of radiographic progression-free survival (HR [95% confidence interval, CI]: 0.54 [0.32-0.93], = 0.03) and time to castration resistance (HR [95% CI]: 0.57 [0.34-0.94], = 0.03) compared with darolutamide + ADT (effective sample size: 319). Time to prostate-specific antigen progression (HR [95% CI]: 0.61 [0.29-1.30], = 0.20) and time to initiation of new antineoplastic therapy (HR [95% CI]: 0.65 [0.34-1.24], = 0.19) favored enzalutamide over darolutamide, albeit the difference was not statistically significant.
[CONCLUSIONS] Enzalutamide + ADT showed better efficacy than darolutamide + ADT for treatment of patients with mHSPC. These findings can help inform treatment decisions in clinical practice.
[PATIENTS AND METHODS] Individual patient data from ARCHES (NCT02677896; enzalutamide + ADT, = 1150) were weighted and adjusted to match published aggregated data on baseline characteristics from ARANOTE (NCT04736199; darolutamide + ADT, = 669). The MAIC was anchored on the common comparator, placebo + ADT, and provided a (matching-adjusted) hazard ratio (HR) of enzalutamide versus darolutamide.
[RESULTS] Treatment with enzalutamide + ADT significantly prolonged the primary endpoint of radiographic progression-free survival (HR [95% confidence interval, CI]: 0.54 [0.32-0.93], = 0.03) and time to castration resistance (HR [95% CI]: 0.57 [0.34-0.94], = 0.03) compared with darolutamide + ADT (effective sample size: 319). Time to prostate-specific antigen progression (HR [95% CI]: 0.61 [0.29-1.30], = 0.20) and time to initiation of new antineoplastic therapy (HR [95% CI]: 0.65 [0.34-1.24], = 0.19) favored enzalutamide over darolutamide, albeit the difference was not statistically significant.
[CONCLUSIONS] Enzalutamide + ADT showed better efficacy than darolutamide + ADT for treatment of patients with mHSPC. These findings can help inform treatment decisions in clinical practice.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Aged
- 80 and over
- Humans
- Male
- Middle Aged
- Androgen Antagonists
- Antineoplastic Combined Chemotherapy Protocols
- Benzamides
- Nitriles
- Phenylthiohydantoin
- Progression-Free Survival
- Prostatic Neoplasms
- Castration-Resistant
- Pyrazoles
- Treatment Outcome
- Androgen receptor pathway inhibitor
- darolutamide
- enzalutamide
- indirect treatment comparison
- metastatic hormone-sensitive prostate cancer
같은 제1저자의 인용 많은 논문 (5)
- Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
- Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.
- ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients.
- Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562].
- Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.